JP2019515042A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515042A5
JP2019515042A5 JP2019510574A JP2019510574A JP2019515042A5 JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5 JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5
Authority
JP
Japan
Prior art keywords
disease
alkyl
compound
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515042A (ja
JP6869331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031352 external-priority patent/WO2017193030A1/en
Publication of JP2019515042A publication Critical patent/JP2019515042A/ja
Publication of JP2019515042A5 publication Critical patent/JP2019515042A5/ja
Priority to JP2021067440A priority Critical patent/JP2021107415A/ja
Application granted granted Critical
Publication of JP6869331B2 publication Critical patent/JP6869331B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510574A 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター Expired - Fee Related JP6869331B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021067440A JP2021107415A (ja) 2016-05-05 2021-04-13 統合ストレス経路のモジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332284P 2016-05-05 2016-05-05
US62/332,284 2016-05-05
PCT/US2017/031352 WO2017193030A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021067440A Division JP2021107415A (ja) 2016-05-05 2021-04-13 統合ストレス経路のモジュレーター

Publications (3)

Publication Number Publication Date
JP2019515042A JP2019515042A (ja) 2019-06-06
JP2019515042A5 true JP2019515042A5 (https=) 2020-06-25
JP6869331B2 JP6869331B2 (ja) 2021-05-12

Family

ID=58710114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510574A Expired - Fee Related JP6869331B2 (ja) 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター
JP2021067440A Pending JP2021107415A (ja) 2016-05-05 2021-04-13 統合ストレス経路のモジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021067440A Pending JP2021107415A (ja) 2016-05-05 2021-04-13 統合ストレス経路のモジュレーター

Country Status (12)

Country Link
US (2) US10864196B2 (https=)
EP (2) EP3778575A1 (https=)
JP (2) JP6869331B2 (https=)
CN (1) CN109641853A (https=)
AR (1) AR108394A1 (https=)
AU (1) AU2017260363B2 (https=)
CA (1) CA3023161A1 (https=)
ES (1) ES2821790T3 (https=)
PT (1) PT3452454T (https=)
TW (1) TW201808914A (https=)
UY (1) UY37231A (https=)
WO (1) WO2017193030A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN112713985B (zh) 2017-05-05 2022-03-08 华为技术有限公司 传输信号的方法和装置
EP3628043A4 (en) * 2017-05-15 2021-04-28 Recurium IP Holdings, LLC ANALGESIC COMPOUNDS
WO2018225093A1 (en) * 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
JP2020522553A (ja) * 2017-06-07 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Atf4経路阻害剤としての化合物
CA3071024A1 (en) 2017-08-09 2019-02-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN111201245B (zh) 2017-09-01 2024-04-05 戴纳立制药公司 化合物、组合物和方法
WO2019090088A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080808A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
JP2021501781A (ja) * 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
AU2018358157B2 (en) * 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
AU2019282253A1 (en) 2018-06-05 2020-11-26 Altos Labs, Inc. Inhibitors of integrated stress response pathway
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
TW202545902A (zh) 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
SG11202108552QA (en) 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
EP3959198A1 (en) 2019-04-23 2022-03-02 Evotec International GmbH Modulators of the integrated stress response pathway
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
PE20220572A1 (es) 2019-04-30 2022-04-20 Calico Life Sciences Llc Moduladores de la via integrada del estres
WO2020252207A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
JP7699595B2 (ja) 2020-01-28 2025-06-27 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合的ストレス応答経路の調節因子
CN115190813B (zh) * 2020-03-11 2024-10-15 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
EP4232153A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
EP4232447A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
RS66455B1 (sr) 2020-10-22 2025-02-28 Evotec Int Gmbh Modulatori puta integrisanog odgovora na stres
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
AU2023384649A1 (en) * 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212A (en) 1847-07-31 Richard m
US162A (en) 1837-04-17 Island
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
UA80459C2 (en) * 2002-12-20 2007-09-25 Merck & Co Inc Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬i
JP5133702B2 (ja) 2005-01-05 2013-01-30 アボット・ラボラトリーズ 11−β−ヒドロキシステロイドデヒドロゲナーゼ1型酵素の阻害薬
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
US8334290B2 (en) * 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
TWI538905B (zh) 2010-12-22 2016-06-21 H 朗德貝克公司 雙環[3.2.1]辛基醯胺衍生物及其用途
CA2904794C (en) * 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
US20160318856A1 (en) 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
CN109641910A (zh) * 2016-06-24 2019-04-16 梅尔莎纳医疗公司 吡咯并苯二氮*及其缀合物

Similar Documents

Publication Publication Date Title
JP2019515042A5 (https=)
JP2019519599A5 (https=)
JP2019515043A5 (https=)
JP2019530649A5 (https=)
RU2022106770A (ru) Модуляторы интегрированного сигнального пути стресса
AU765473B2 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
AU2015337607B2 (en) Substituted dihydropyrrolopyrazole compound
CN114729044B (zh) 毒蕈碱型乙酰胆碱m1受体拮抗剂
WO2015101928A1 (en) Fused thiophene and thiazole derivatives as ror gamma modulators
AU2019217320B2 (en) Steroid derivative regulators, method for preparing the same, and uses thereof
AU2020353663B2 (en) Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease
JP2019508407A5 (https=)
AU2004215481A1 (en) Pyrazolo(1,5-A)pyrimidine derivatives
JP2009534407A5 (https=)
HRP20161010T1 (hr) C5ar antagonisti
JP2021501781A5 (https=)
JP2017502088A5 (https=)
JP2009534406A5 (https=)
JP2017538712A5 (https=)
DE69414085T2 (de) Wirkstoff zum schutze von gehirnzellen
AU2019389017B2 (en) Methods of treating disease with MAGL inhibitors
CA3043612A1 (en) Magl inhibitors
HRP20230518T1 (hr) Heteroarilfenoksibenzamidni opioidni ligandi kapa
MX2011006343A (es) Tiazoles como ligandos del receptor de cannabinoide.
JPWO2020223536A5 (https=)